RAS Quantification in Patients With Aliskiren or Candesartan
Launched by MEDICAL UNIVERSITY OF VIENNA · Apr 8, 2013
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic kidney disease stages III-IV (defined by modification of diet in renal disease (MDRD) formula)
- • Urinary albumin to creatinine ratio (UACR) \>300mg/g, UACR \>200mg/g if already receiving RAS blockade
- • Arterial hypertension
- Exclusion Criteria:
- • Age \<18 years
- • Diabetes mellitus type 2 (defined by WHO criteria)
- • Chronic kidney disease stage V (end-stage renal disease)
- • UACR \>3500mg/g
- • Severe hypertension (systolic blood pressure \>180mmHg)
- • Pregnancy
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Marcus D Saemann, MD
Principal Investigator
Medical University of Vienna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials